Study drug PT886 for gastric and pancreatic adenocarcinoma (PT886X1101) - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

¿Cuál es el Propósito de este estudio?

We are doing this study to see if the study drug, PT886, with or without chemotherapy and/or pembrolizumab, is a safe and effective option for gastric and pancreatic cancer. We are also trying to find the best dose of the study drug to use.

¿Cuál es la Condición que se está estudiando?

Gastric and Pancreatic Adenocarcinoma

¿Quién puede participar en el Estudio?

Adults ages 18+ who are diagnosed with an advanced or metastatic cancer of the following types:

Gastric or gastroesophageal junction adenocarcinoma; OR
Pancreatic ductal adenocaricnoma

For more information, contact the study team at dana.a.warren@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Receive infusions of PT886 every 1 to 3 weeks
Depending on which arm of the study you are in, you may also get chemotherapy and/or pembrolizumab
Hágase biopsia del tumor
Give blood and urine samples
Realice tomografías computarizadas o resonancias magnéticas de manera regular.

Detalles del Estudio

Título Completo

[PT886X1101] A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination with ChemotherApy and/or an Immune ChecKpoint Inhibitor

Investigador Principal